Daniel Catenacci retweeted
🚨PRODIGE23🚨
Long term results now published!
T3-4 rectal adenocarcinoma
Randomized:
CRT➡️🔪➡️FOLFOX
mFOLFIRINOX ➡️ CRT➡️🔪➡️FOLFOX
✅✅✅Improved OS!!!
Looking forward to JANUS clarifying if TNT with FOLFIRINOX vs. FOLFOX improves cCR and/or DFS/OS
pubmed.ncbi.nlm.nih.gov/3898…
Daniel Catenacci retweeted
🔥 ASCO 2024 Plenary: Prof Dr @JDekervel (UZ Leuven) and Prof Dr @FlorianLordick (University of Leipzig) discuss the ESOPEC trial, comparing FLOT perioperative chemotherapy with neoadjuvant chemoradiotherapy for adenocarcinoma of the oesophagus or oesophagogastric junction.
Daniel Catenacci retweeted
Yes research warranted, not SOC. Control here arm did very well compared to overt stage IV disease, as expected, since these are highly selected patients. This control arm is so critical because it normalizes and shows that they do well, but not due to the surgical intervention.
Daniel Catenacci retweeted
I guess we must agree to disagree until we see prospective phase 3 data. Thankfully others have actually done this study and asked this very pertinent question as to the utility of RT in EGJ AC and not danced around it for 20+ years. Would you change your opinion based on esopec?
Daniel Catenacci retweeted
Replying to @ILSONDavid @RenoHemonc
Do you call the benefit of CROSS over surgery alone ‘modest’ with a HR of 0.75? FLOT had HR of 0.76 over ECF which previously had a HR of 0.74 over surgery alone. There is nothing more to say. Ultimately you either see it and it is obvious or you dont. But you eventually will.
Daniel Catenacci retweeted
Unfair comparison of ITT R0 in FLOT vs R0 of those going to surgery in CROSS. Also,Why compare surrogate endpnts of OS when we actually have the OS to compare? The controlled studies are coming.Will be some disappointed folks likely. See here: meetinglibrary.asco.org/reco… @RenoHemonc
Daniel Catenacci retweeted
Looking forward to debating Dr Ilson!! (FLOT vs CROSS #31.)@agrothey @ILSONDavid
Looking forward to discussions with my colleagues during Great Debates in GI Malignancies next week! @GreatDebatesGI
Daniel Catenacci retweeted
#justmath
I particularly like the comment that this is homework for 9-yr olds...@GermanBiotech
CROSS-trial comparisons r tricky, but it's the HR compared to controls that are useful here...
Of course we await ESOPEC, but for now, the evidence points in a certain direction...no?
Daniel Catenacci retweeted
Hey #medtwitter, I need some help with the math on this one:
@OncoAlert
If B - A = X
& C - A = X
& B=C
& D - B = X
& D - C = Y
Can we solve for Y?
2%Y=Z
2%Y=A
85%Y=X
10%Indeterminate
206 votes • Final results Daniel Catenacci retweeted
Last, I would say that ~90% of pts will have a PET response w FLOT, & we saw this also w FOLFIRINOX. These pts are not at risk for R1 resection. One might consider CROSS for those ~10% who don’t, with the caveat that those are the resilient tumors that may also be radioresistant.
Daniel Catenacci retweeted
Tweet 6/6:
From tweet 5/6, if we have a prospective study that seeks organ preservation, documents differences in QOL, & risk of local/distant recurrence & OS comparing dCRT vs, hopefully what is now everyone’s standard, perioperative FLOT, then great, & pts can make a choice.
Daniel Catenacci retweeted
Tweet 5/6:
If an appropriately designed study shows that dCRT can safely (i.e. Not lower survival, or at least quantify if there is a detriment in survival what the actual detriment is so pts can make an informed decision) replace surgery with perioperative FLOT for AC, great.
Daniel Catenacci retweeted
Tweet 4/6 part3:
Organ preservation is not in the conversation here in the current study. This is about what is the optimal perioperative therapy as an adjunct to the main course, surgery. The question of whether or not surgery can be replaced by dCRT needs a prospective study.
Daniel Catenacci retweeted
Tweet 4/6 part2:
I think a study FLOT vs FLOT-CRT is reasonable. TOPGEAR assesses this after the FLOT amendment, but not including type I Seiwert and mostly gastric. Either way I don’t think it will change OS in the FLOT subgroup, but let’s see.
Daniel Catenacci retweeted
Tweet 4/6:
If u can ⬇️ local recurrence, despite not having any improvement in OS, one might argue that this could help for palliation. Counterpoint would be RT to palliate only those ~10% who recur not everybody. The presenter indicated that local recurrence was ⬇️ in both arms.
Daniel Catenacci retweeted
Tweet 3/6 part2:
I think the presenter indicated that if they did not get chemo for at least 1 of the 5 planned doses they were considered not getting all tx. But it is very common to not get the 4th and/or 5th dose due to cytopenias. But nearly 100% completed the RT component.
Daniel Catenacci retweeted
Tweet 3/6 part1:
Yes, the median OS in CROSS Arm lower than original. To me this was expected because patients with T4a & N2 disease were not excluded here, like they were in the original CROSS study. ie worse prognosis pts with worse outcome. FLOT4 had these pts, as does ESOPEC.
Daniel Catenacci retweeted
Tweet 2/6:
- yes this is always about AC only. CRT for SCC.
-T4b tumors are not resectable. ie palliative C & dCRT & hope for the best. Maybe a few convert.
-For N0 tumors, still trend to benefit in this small subgroup. More relevant question would be, ‘would FOLFOX suffice?’
Daniel Catenacci retweeted
Replying to @NiuSanford @SuyogCancer
My thoughts:
Your tweet 1/6:
Over the years a lot of people predicted that MAGIC and FLOT would be worse than CROSS- I know this because I debated and argued about it for 15 years with them. But ok, let’s say ‘as predicted’ 😏
Daniel Catenacci retweeted
Curious others thoughts on this take @SuyogCancer @DocCatenacci











